LONDON, April 7 (Reuters) - Britain's recommendation against giving the Oxford-AstraZeneca COVID-19 vaccine to those aged under 30 due to the risk of blood clots will have a negligible impact on the vaccine programme, England's deputy chief medical officer Jonathan Van-Tam said.
   "Because of our supply situation in relation to alternative vaccines, the effect on the timing of our overall programme should be zero or negligible," he said at a briefing on Wednesday.

(Reporting by Guy Faulconbridge and Kate Holton, Writing by
Paul Sandle; editing by James Davey)
((paul.sandle@thomsonreuters.com; +44 20 7542 6843; Reuters
Messaging: paul.sandle.thomsonreuters.com@reuters.net)